All stocks today
71229 stocks real-time data.
All stocks today

Stock quotes

Stock market live

Historical stock prices

Stocks market capitalization

Dividend stocks

Stock earnings

Stock revenue

Stock ratings. Where to invest?

Mitsubishi Tanabe Pharma Corporation revenue reports

Mitsubishi Tanabe Pharma Corporation financial reports, Mitsubishi Tanabe Pharma Corporation annual revenue in 2024. When does Mitsubishi Tanabe Pharma Corporation report revenue?
Add to widgets
Added to widgets

Mitsubishi Tanabe Pharma Corporation total revenue, net income and dynamics of changes in US dollar today

Mitsubishi Tanabe Pharma Corporation revenue for the past few reporting periods. The dynamics of Mitsubishi Tanabe Pharma Corporation net income went up. The change was 8 470 000 000 $. Net income, revenue and dynamics - the main financial indicators of Mitsubishi Tanabe Pharma Corporation. The financial schedule of Mitsubishi Tanabe Pharma Corporation consists of three charts of the main financial indicators of the company: total assets, net revenue, net income. The financial report chart shows the values from 30/06/2018 to 31/12/2019. A graph of the value of all Mitsubishi Tanabe Pharma Corporation assets is presented in green bars.

Report date Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
and Change (%)
Comparing current quartal report this year to quartal report last year.
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
and Change (%)
Comparing current quartal report this year to quartal report last year.
31/12/2019 109 305 000 000 $ -10.967 % ↓ 9 906 000 000 $ -39.88 % ↓
30/09/2019 89 997 000 000 $ -13.762 % ↓ 1 436 000 000 $ -86.983 % ↓
30/06/2019 98 112 000 000 $ -6.871 % ↓ 6 881 000 000 $ -50.706 % ↓
31/03/2019 92 288 000 000 $ - -4 096 000 000 $ -
31/12/2018 122 769 000 000 $ - 16 477 000 000 $ -
30/09/2018 104 359 000 000 $ - 11 032 000 000 $ -
30/06/2018 105 351 000 000 $ - 13 959 000 000 $ -
Show:
to

Mitsubishi Tanabe Pharma Corporation financial report charts

The latest dates of Mitsubishi Tanabe Pharma Corporation financial statements available online: 30/06/2018, 30/09/2019, 31/12/2019. Dates and dates of financial statements are established by the laws of the country where the company operates. The current date of the financial report of Mitsubishi Tanabe Pharma Corporation for today is 31/12/2019. Gross profit Mitsubishi Tanabe Pharma Corporation is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services. Gross profit Mitsubishi Tanabe Pharma Corporation is 54 748 000 000 $

Mitsubishi Tanabe Pharma Corporation quarterly report dates

Cost of revenue Mitsubishi Tanabe Pharma Corporation is the total cost of producing and distributing of products and services of a company. Cost of revenue Mitsubishi Tanabe Pharma Corporation is 54 557 000 000 $ Total revenue Mitsubishi Tanabe Pharma Corporation refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods. Total revenue Mitsubishi Tanabe Pharma Corporation is 109 305 000 000 $ Operating income Mitsubishi Tanabe Pharma Corporation is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS). Operating income Mitsubishi Tanabe Pharma Corporation is 12 423 000 000 $

Net income Mitsubishi Tanabe Pharma Corporation is an entity's income minus cost of goods sold, expenses and taxes for an accounting period. Net income Mitsubishi Tanabe Pharma Corporation is 9 906 000 000 $ Current assets Mitsubishi Tanabe Pharma Corporation is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year. Current assets Mitsubishi Tanabe Pharma Corporation is 603 933 000 000 $ Total assets Mitsubishi Tanabe Pharma Corporation refers to the total amount of assets owned by a person or entity. Total assets Mitsubishi Tanabe Pharma Corporation is 1 077 547 000 000 $

31/12/2019 30/09/2019 30/06/2019 31/03/2019 31/12/2018 30/09/2018 30/06/2018
Gross profit
Gross profit is the profit a company makes after deducting the costs of making and selling its products, or the costs of providing its services.
54 748 000 000 $ 46 253 000 000 $ 53 348 000 000 $ 50 843 000 000 $ 69 702 000 000 $ 60 575 000 000 $ 63 001 000 000 $
Cost of revenue
Cost of revenue is the total cost of producing and distributing of products and services of a company.
54 557 000 000 $ 43 744 000 000 $ 44 764 000 000 $ 41 445 000 000 $ 53 067 000 000 $ 43 784 000 000 $ 42 350 000 000 $
Total revenue
Total revenue refers to the total receipts from sales of a given quantity of goods or services. It is the total income of a business and is calculated by multiplying the quantity of goods sold by the price of the goods.
109 305 000 000 $ 89 997 000 000 $ 98 112 000 000 $ 92 288 000 000 $ 122 769 000 000 $ 104 359 000 000 $ 105 351 000 000 $
Operating revenue
Operating revenue is revenue generated from a company's primary business activities. For example, a retailer produces revenue through merchandise sales, and a physician derives revenue from the medical services he/she provides.
- - - - - - -
Operating income
Operating income is an accounting figure that measures the amount of profit realized from a business's operations, after deducting operating expenses such as wages, depreciation and cost of goods sold (COGS).
12 423 000 000 $ 2 939 000 000 $ 9 616 000 000 $ -379 000 000 $ 22 027 000 000 $ 15 193 000 000 $ 19 300 000 000 $
Net income
Net income is an entity's income minus cost of goods sold, expenses and taxes for an accounting period.
9 906 000 000 $ 1 436 000 000 $ 6 881 000 000 $ -4 096 000 000 $ 16 477 000 000 $ 11 032 000 000 $ 13 959 000 000 $
R&D spending
Research and Development spending - cost of investigative activities to improve existing products and procedures or to lead to the development of new products and procedures.
17 761 000 000 $ 19 863 000 000 $ 19 930 000 000 $ 24 627 000 000 $ 22 351 000 000 $ 19 907 000 000 $ 19 648 000 000 $
Operating expense
An operating expense is an expenditure that a business incurs as a result of performing its normal business operations.
96 882 000 000 $ 87 058 000 000 $ 88 496 000 000 $ 92 667 000 000 $ 100 742 000 000 $ 89 166 000 000 $ 86 051 000 000 $
Current assets
Current assets is a balance sheet item that represents the value of all assets that can reasonably expect to be converted into cash within one year.
603 933 000 000 $ 590 125 000 000 $ 574 671 000 000 $ 588 433 000 000 $ 583 984 000 000 $ 589 181 000 000 $ 563 830 000 000 $
Total assets
Total assets refers to the total amount of assets owned by a person or entity.
1 077 547 000 000 $ 1 055 880 000 000 $ 1 045 456 000 000 $ 1 056 286 000 000 $ 1 051 513 000 000 $ 1 070 941 000 000 $ 1 033 346 000 000 $
Current cash
Current cash - the sum of all of the cash a company has on the date of report.
97 657 000 000 $ 88 545 000 000 $ 105 379 000 000 $ 111 850 000 000 $ 109 186 000 000 $ 122 088 000 000 $ 106 498 000 000 $
Current debt
Current debt is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital.
100 243 000 000 $ 88 393 000 000 $ 86 661 000 000 $ 91 450 000 000 $ 86 506 000 000 $ 91 116 000 000 $ 76 079 000 000 $
Total cash
Total cash - the sum of all of the cash a company has on its books, including petty cash and funds on deposit in a bank.
- - - - - - -
Total debt
Total debt is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year.
186 831 000 000 $ 162 294 000 000 $ 151 511 000 000 $ 145 954 000 000 $ 141 014 000 000 $ 149 805 000 000 $ 132 541 000 000 $
Debt ratio
Total debt to total assets - is a financial ratio that indicates the percentage of a company's assets that are provided via debt.
17.34 % 15.37 % 14.49 % 13.82 % 13.41 % 13.99 % 12.83 %
Shareholders equity
Shareholder's equity (SE) is the owner's claim after subtracting total liabilities from total assets.
878 095 000 000 $ 881 550 000 000 $ 881 185 000 000 $ 897 604 000 000 $ 898 360 000 000 $ 908 216 000 000 $ 888 321 000 000 $
Cash flow
Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business.
12 805 000 000 $ 14 244 000 000 $ 5 243 000 000 $ 11 992 000 000 $ 5 971 000 000 $ 22 888 000 000 $ 609 000 000 $

Last revenue report of Mitsubishi Tanabe Pharma Corporation was 31/12/2019. According to last financial report total revenue in Mitsubishi Tanabe Pharma Corporation was 109 305 000 000 US dollar and changed by -10.967% since last year. Net income in Mitsubishi Tanabe Pharma Corporation was 9 906 000 000 $ in last quartal, net income changes to -39.88%.

Current cash Mitsubishi Tanabe Pharma Corporation - the sum of all of the cash a company has on the date of report. Current cash Mitsubishi Tanabe Pharma Corporation is 97 657 000 000 $ Current debt Mitsubishi Tanabe Pharma Corporation is the portion of debt due within a year (12 months) and is listed as a current liability and part of net working capital. Current debt Mitsubishi Tanabe Pharma Corporation is 100 243 000 000 $ Total debt Mitsubishi Tanabe Pharma Corporation is a combination of both short-term and long-term debt. Short-term debts are those that must be paid back within a year. Long-term debt generally includes every liability that must be paid off in more than a year. Total debt Mitsubishi Tanabe Pharma Corporation is 186 831 000 000 $

Mitsubishi Tanabe Pharma Corporation stocks data

Mitsubishi Tanabe Pharma Corporation financials